[1. Clifford BD, Donahue D, Smith L, Cable E, Luttig B, Manns M, et al. High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology. 1995;21(3):613-9. DOI: 10.1016/0270-9139(95)90507-3 DOI: 10.1002/hep.1840210302.10.1016/0270-9139(95)90507-3]Search in Google Scholar
[2. Bonnet F, Pineau JJ, Taupin JL, Feyler A, Bonarek M, de WS, et al. Prevalence of cryoglobulinemia and serological markers of autoimmunity in human immunodeficiency virus infected individuals: a cross-sectional study of 97 patients. JRheumatol. 2003;30(9):2005-10.]Search in Google Scholar
[3. Imran A, Neelam F, Tariq M. Incidence of circulating antinuclear antibodies in cancer patients. Indian JMedSci. 2003;57(3):113-6.]Search in Google Scholar
[4. Qadan LR, Ahmed AA, Abdel-Jalil S, Al-Bader MA. Significance of antinuclear antibodies and rheumatoid factor in patients with advanced peripheral arterial disease. MedPrincPract. 2010;19(3):192-5. DOI: 10.1159/000273071.10.1159/000273071]Search in Google Scholar
[5. Rich S, Kieras K, Hart K, Groves BM, Stobo JD, Brundage BH. Antinuclear antibodies in primary pulmonary hypertension. JAmCollCardiol. 1986;8(6):1307-11. DOI: 10.1016/s0735-1097(86)80301-1.10.1016/S0735-1097(86)80301-1]Search in Google Scholar
[6. Yukawa N, Fujii T, Kondo-Ishikawa S, Yoshifuji H, Kawabata D, Nojima T, et al. Correlation of antinuclear antibody and anti-double-stranded DNA antibody with clinical response to infliximab in patients with rheumatoid arthritis: a retrospective clinical study. Arthritis ResTher. 2011;13(6):R213. DOI: 10.1186/ar3546.10.1186/ar3546333466622192852]Search in Google Scholar
[7. Nisihara R, Kubis MM, Rodrigues PC, Skare T, Mocelin V, Utiyama S. Antinuclear antibodies and rheumatoid factor positivity in healthy elderly adults: a cross-sectional study in 336 individuals. JAmGeriatrSoc. 2013;61(11):2044-6. DOI: 10.1111/jgs.12533.10.1111/jgs.1253324219209]Search in Google Scholar
[8. Nishimura S, Nishiya K, Hisakawa N, Chikazawa H, Ookubo S, Nakatani K, et al. Positivity for antinuclear antibody in patients with advanced rheumatoid arthritis. Acta MedOkayama. 1996;50(5):261-5.]Search in Google Scholar
[9. Muzellec Y, Le GP, Jouquan J, Fauquert P, Muller S, Youinou P. Antibodies to histones in rheumatoid arthritis. DiagnClinImmunol. 1988;5(6):326-31.]Search in Google Scholar
[10. Glossop JR, Dawes PT, Mattey DL. Antinuclear antibodies are associated with tumor necrosis factor receptor I gene polymorphism in patients with rheumatoid arthritis. ClinExpRheumatol. 2011;29(4):609-15.]Search in Google Scholar
[11. Jacobsen S. Young age of onset is associated with increased prevalence of circulating IgM rheumatoid factor and antinuclear antibodies at presentation in women with rheumatoid arthritis. ClinRheumatol. 2004;23(2):121-2. DOI: 10.1007/s10067-003-0844-9.10.1007/s10067-003-0844-915045625]Search in Google Scholar
[12. Caspi D, Elkayam O, Eisinger M, Vardinon N, Yaron M, Burke M. Clinical significance of low titer anti-nuclear antibodies in early rheumatoid arthritis: implications on the presentation and long-term course of the disease. RheumatolInt. 2001;20(2):43-7. DOI: 10.1007/ s002960000073.10.1007/s00296000007311269531]Search in Google Scholar
[13. Young A, Koduri G. Extra-articular manifestations and complications of rheumatoid arthritis. BestPractResClinRheumatol. 2007;21(5):907-27. DOI: 10.1016/j.berh.2007.05.007.10.1016/j.berh.2007.05.00717870035]Search in Google Scholar
[14. Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. AnnRheumDis. 2014;73(3):492-509. DOI: 10.1136/annrheumdis-2013-204573.10.1136/annrheumdis-2013-204573393307424161836]Search in Google Scholar
[15. Jilani AA, Mackworth-Young CG. The role of citrullinated protein antibodies in predicting erosive disease in rheumatoid arthritis: a systematic literature review and meta-analysis. IntJRheumatol. 2015;2015:728610. DOI: 10.1155/2015/728610.10.1155/2015/728610436437025821469]Search in Google Scholar
[16. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, III, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/ European League Against Rheumatism collaborative initiative. AnnRheumDis. 2010;69(9):1580-8. DOI: 10.1002/art.27584 DOI: 10.1136/ard.2010.138461.10.1002/art.2758420872595]Search in Google Scholar
[17. Prevoo ML, van ‘t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis Arthritis Rheum. 1995;38(1):44-8. DOI: 10.1002/ art.1780380107.10.1002/art.17803801077818570]Search in Google Scholar
[18. Innala L, Berglin E, Moller B, Ljung L, Smedby T, Sodergren A, et al. Age at onset determines severity and choice of treatment in early rheumatoid arthritis: a prospective study. Arthritis research & therapy. 2014;16(2):R94. DOI: 10.1186/ar4540.10.1186/ar4540406026324731866]Search in Google Scholar
[19. Amaya-Amaya J, Calixto OJ, Saade-Lemus S, Calvo- Paramo E, Mantilla RD, Rojas-Villarraga A, et al. Does non-erosive rheumatoid arthritis exist? A cross-sectional analysis and a systematic literature review. Seminars in arthritis and rheumatism. 2015;44(5):489-98. DOI: 10.1016/j.semarthrit.2014.09.006.10.1016/j.semarthrit.2014.09.00625440525]Search in Google Scholar
[20. Rodriguez-Carrio J, Alperi-Lopez M, Lopez P, Alonso- Castro S, Ballina-Garcia FJ, Suarez A. Angiogenic T cells are decreased in rheumatoid arthritis patients. Annals of the rheumatic diseases. 2015;74(5):921-7. DOI: 10.1136/annrheumdis-2013-204250.10.1136/annrheumdis-2013-20425024399233]Search in Google Scholar
[21. Mathieu S, Couderc M, Pereira B, Soubrier M. The effects of TNF-alpha inhibitor therapy on arterial stiffness and endothelial dysfunction in rheumatoid arthritis: a meta-analysis. Seminars in arthritis and rheumatism. 2013;43(3):e1-2. DOI: 10.1016/j.semarthrit.2013.05.005.10.1016/j.semarthrit.2013.05.00523810615]Search in Google Scholar
[22. Hsue PY, Scherzer R, Grunfeld C, Imboden J, Wu Y, Del Puerto G, et al. Depletion of B-cells with rituximab improves endothelial function and reduces inflammation among individuals with rheumatoid arthritis. Journal of the American Heart Association. 2014;3(5):e001267. DOI: 10.1161/JAHA.114.001267.10.1161/JAHA.114.001267432382725336464]Search in Google Scholar
[23. Lima A, Monteiro J, Bernardes M, Sousa H, Azevedo R, Seabra V, et al. Prediction of methotrexate clinical response in Portuguese rheumatoid arthritis patients: implication of MTHFR rs1801133 and ATIC rs4673993 polymorphisms. BioMed research international. 2014;2014:368681. DOI: 10.1155/2014/368681.10.1155/2014/368681405537824967362]Search in Google Scholar
[24. Sawalha AH, Harley JB. Antinuclear autoantibodies in systemic lupus erythematosus. CurrOpinRheumatol. 2004;16(5):534-40. DOI: 10.1097/01. bor.0000135452.62800.8f.10.1097/01]Search in Google Scholar
[25. Smeenk RJ. Antinuclear antibodies: cause of disease or caused by disease? Rheumatology(Oxford). 2000;39(6):581-4. DOI: 10.1093/rheumatology/39.6.581.10.1093/rheumatology/39.6.58110888701]Search in Google Scholar
[26. Picerno V, Ferro F, Adinolfi A, Valentini E, Tani C, Alunno A. One year in review: the pathogenesis of rheumatoid arthritis. Clinical and experimental rheumatology. 2015;33(4):551-8.]Search in Google Scholar